Skip to main content
SpringerLink
Log in
Book cover

Sjögren’s Syndrome pp 209–225Cite as

Raynaud’s Phenomenon and Sjögren’s Syndrome

  • Chapter
  • First Online:

  • 1256 Accesses

Abstract

In 1862, Maurice Raynaud published his medical school thesis in which he argued that some people have transient digital ischemia when exposed to cold temperatures. It is now recognized that skin blood flow in humans provides an important mechanism for normal thermoregulation. In fact, a normal response to cold exposure is vasoconstriction of the cutaneous blood vessels, leading to a decrease in heat loss from the body and protection against hypothermia [1].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. 2003;78:603–12.

    Article  PubMed  Google Scholar 

  2. Thompson-Torgerson CS, Holowatz LA, Kenney WL. Altered mechanisms of thermoregulatory vasoconstriction in aged human skin. Exerc Sport Sci Rev. 2008;36:122–7.

    Article  PubMed  Google Scholar 

  3. Chikura B, Moore TL, Manning JB, et al. Sparing of the thumb in Raynaud’s phenomenon. Rheumatology (Oxford). 2008;47:219–21.

    Article  CAS  Google Scholar 

  4. Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud’s phenomenon in an inner city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol. 1999;52:441–6.

    Article  PubMed  CAS  Google Scholar 

  5. Block JA, Sequeira W. Raynaud’s phenomenon. Lancet. 2001;357:2042–8.

    Article  PubMed  CAS  Google Scholar 

  6. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs. Tarentaise, Savoie, France. J Rheumatol. 1993;20:70–6.

    PubMed  CAS  Google Scholar 

  7. LeRoy EC, Medsger Jr TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485–8.

    PubMed  CAS  Google Scholar 

  8. Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295:1149–54.

    Article  PubMed  CAS  Google Scholar 

  9. Tuffanelli DL, Winkelmann RK. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol. 1961;84:359–71.

    PubMed  CAS  Google Scholar 

  10. Parker MD. Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease. J Lab Clin Med. 1973;82:769–75.

    PubMed  CAS  Google Scholar 

  11. Cohen ML, Dawkins B, Dawkins RL, et al. Clinical significance of antibodies to ribonucleoprotein. Ann Rheum Dis. 1979;38:74–8.

    Article  PubMed  CAS  Google Scholar 

  12. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971;50:85–95.

    CAS  Google Scholar 

  13. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinicolaboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985;64:285–95.

    CAS  Google Scholar 

  14. Saraux A, Allain J, Guedes C, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752–4.

    Article  PubMed  CAS  Google Scholar 

  15. De Angelis R, Cerioni A, Del Medico P, et al. Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol. 2005;24:145–51.

    Article  PubMed  Google Scholar 

  16. Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002;29:2345–9.

    PubMed  Google Scholar 

  17. Youinou P, Pennec YL, Katsikis P, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Br J Rheumatol. 1990;29:205–7.

    Article  PubMed  CAS  Google Scholar 

  18. Skopouli FN, Talal A, Galanopoulou V, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. J Rheumatol. 1990;17:618–20.

    PubMed  CAS  Google Scholar 

  19. Kraus A, Caballero-Uribe C, Jakez J, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Association with other extraglandular manifestations. J Rheumatol. 1992;19:1572–4.

    PubMed  CAS  Google Scholar 

  20. Garcia-Carrasco M, Sisó A, Ramos-Casals M, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002;29:726–30.

    PubMed  Google Scholar 

  21. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol. 1997;24:879–89.

    PubMed  CAS  Google Scholar 

  22. Kraus A, Guerra-Bautista G, Espinoza G, et al. Defects of the retinal pigment epithelium in scleroderma. Br J Rheumatol. 1991;30:112–4.

    Article  PubMed  CAS  Google Scholar 

  23. Diaz-López C, Geli C, Corominas H, et al. Are there clinical or serological differences between male and female patients with primary Sjögren’s syndrome? J Rheumatol. 2004;31:1352–5.

    PubMed  Google Scholar 

  24. Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009;48:iii19–24.

    Article  Google Scholar 

  25. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210–9.

    Article  CAS  Google Scholar 

  26. Willeke P, Schlüter B, Schotte H, et al. Interferon-gamma is increased in patients with primary Sjögren’s syndrome and Raynaud’s phenomenon. Semin Arthritis Rheum. 2009;39:197–202.

    Article  PubMed  CAS  Google Scholar 

  27. Foster H, Kelly C, Griffiths I. Raynaud’s phenomenon and primary Sjögren’s syndrome. Br J Rheumatol. 1990;29:493–4.

    Article  PubMed  CAS  Google Scholar 

  28. Ramos-Casals M, Nardi N, Brito-Zerón P, et al. Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006;35:312–21.

    Article  PubMed  CAS  Google Scholar 

  29. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other ­systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246–55.

    Article  PubMed  Google Scholar 

  30. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum. 2004;50:882–91.

    Article  PubMed  Google Scholar 

  31. Font J, Ramos-Casals M, Cervera R, et al. Antineutrophil cytoplasmic antibodies in primary Sjögren’s syndrome: prevalence and clinical significance. Br J Rheumatol. 1998;37:1287–91.

    Article  PubMed  CAS  Google Scholar 

  32. Hernandez-Molina G, Avila-Casado C, Cardenas-Velazquez F, et al. Similarities and differences between primary and secondary Sjögren’s syndrome. J Rheumatol. 2010;37(4):800–8.

    Article  PubMed  Google Scholar 

  33. Kallenberg CG, Pastoor GW, Wouda AA. Antinuclear antibodies in patients with Raynaud’s phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982;41:382–7.

    Article  PubMed  CAS  Google Scholar 

  34. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902–12.

    Article  PubMed  Google Scholar 

  35. Gelber AC, Pillemer SR, Baum BJ, et al. Distinct recognition of antibodies to centromere proteins in primary Sjögren’s syndrome compared with limited scleroderma. Ann Rheum Dis. 2006;65:1028–32.

    Article  PubMed  CAS  Google Scholar 

  36. Salliot C, Gottenberg JE, Bengoufa D, et al. Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34:2253–8.

    PubMed  CAS  Google Scholar 

  37. Katano K, Kawano M, Koni I, et al. Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol. 2001;28:2238–44.

    PubMed  CAS  Google Scholar 

  38. Tektonidou M, Kaskani E, Skopouli FN, et al. Microvascular abnormalities in Sjögren’s syndrome: nailfold capillaroscopy. Rheumatology. 1999;38:826–30.

    Article  PubMed  CAS  Google Scholar 

  39. Caramaschi P, Biasi D, Carletto A, et al. Sjögren’s syndrome with anticentromere antibodies. Rev Rhum Engl Ed. 1997;64:785–8.

    PubMed  CAS  Google Scholar 

  40. Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, et al. Anticentromere antibody positive Sjogren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010;12(2):R47.

    Article  PubMed  Google Scholar 

  41. Miyawaki S, Asanuma H, Nishiyama S, et al. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol. 2005;32:1488–94.

    PubMed  Google Scholar 

  42. Vlachoyiannopoulos PG, Drosos AA, Wiik A, et al. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol. 1993;32:297–301.

    Article  PubMed  CAS  Google Scholar 

  43. Masayuki I, Kojima T, Miyata M, et al. Primary biliary cirrhosis (PBC)-CREST (Calcinosis, Raynaud’s phenomenon, esophageal dysfunction, Sclerodactyly and telangiectasia) overlap syndrome complicated by Sjögren’s syndrome and arthritis. Intern Med. 1995;34:451–4.

    Article  Google Scholar 

  44. Nakamura T, Higashi S, Tomoda K, et al. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol. 2007;26:596–600.

    Article  PubMed  Google Scholar 

  45. O’Keefe ST, Tsapatsaris NP, Beetham Jr WP. Association between Raynaud’s phenomenon and migraine in a random population of hospital employees. J Rheumatol. 1993;20:1187–8.

    Google Scholar 

  46. Pal B, Gibson C, Passmore J, et al. A study of headaches and migraine in Sjögren’s syndrome and other rheumatic disorders. Ann Rheum Dis. 1989;48:312–6.

    Article  PubMed  CAS  Google Scholar 

  47. Gökçay F, Öder G, Çelebisoy N, et al. Headache in primary Sjögren’s syndrome: a prevalence study. Acta Neurol Scand. 2008;118:189–92.

    Article  PubMed  Google Scholar 

  48. Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med. 2009;30:429–39.

    Article  PubMed  Google Scholar 

  49. Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86:299–315.

    Article  Google Scholar 

  50. Vassilliou VA, Moyssakis I, Boki KA, et al. Is the heart affected in primary Sjögren’s syndrome? An echocardiographic study. Clin Exp Rheumatol. 2008;26:109–12.

    Google Scholar 

  51. Hassoun PM. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med. 2009;3:187–96.

    Article  PubMed  Google Scholar 

  52. Abdelhady K, Gramling-Babb P, Awad S, et al. Current and future therapy for pulmonary hypertension in patients with right and left heart failure. Expert Rev Cardiovasc Ther. 2010;8:241–50.

    Article  PubMed  Google Scholar 

  53. Pirildar T, Tikiz C, Ozkaya S, et al. Endothelial dysfunction in patients with primary Sjögren’s syndrome. Rheumatol Int. 2005;25:536–9.

    Article  PubMed  Google Scholar 

  54. Garcia-Carrasco M, Pizcueta P, Cervera R, et al. Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2000;59:297–9.

    Article  PubMed  CAS  Google Scholar 

  55. Inaoki M, Sato S, Shimada Y, et al. Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipo-prostaglandin E1. J Dermatol Sci. 2001;25:78–82.

    Article  PubMed  CAS  Google Scholar 

  56. Stafford L, Englert H, Gover J, et al. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis. 1998;57:476–9.

    Article  PubMed  CAS  Google Scholar 

  57. Allanore Y, Seror R, Chevrot A, et al. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum. 2007;56:2747–54.

    Article  PubMed  CAS  Google Scholar 

  58. Colakoğu M, Cobankara V, Akpolat T. Effect of clonazepam on Raynaud’s phenomenon and fingertip ulcers in scleroderma. Ann Pharmacother. 2007;41:1544–7.

    Article  Google Scholar 

  59. Raynaud’s Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160:1101–8.

    Article  Google Scholar 

  60. Wigley FM, Korn JH, Csuka ME. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41:670–7.

    Article  PubMed  CAS  Google Scholar 

  61. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841–7.

    Article  PubMed  CAS  Google Scholar 

  62. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44:145–50.

    Article  CAS  Google Scholar 

  63. Rhedda A, McCans J, Willan AR, et al. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol. 1985;12:724–7.

    PubMed  CAS  Google Scholar 

  64. Wigley FM, Flavahan NA. Raynaud’s phenomenon. Rheum Dis Clin North Am. 1996;22:765–81.

    Article  PubMed  CAS  Google Scholar 

  65. Harding SE, Tingey PC, Pope J, et al. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998;(2):CD000956.

    Google Scholar 

  66. Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2 C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 2004;50:3994–4001.

    Article  PubMed  CAS  Google Scholar 

  67. Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg Am. 2009;34:446–52.

    Article  PubMed  Google Scholar 

  68. Van Beek AL, Lim PK, Gear AJ, et al. Management of vasospastic disorders with Botulinum toxin A. Plast Reconstr Surg. 2007;119:217–26.

    Article  PubMed  Google Scholar 

  69. Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am. 2005;31:177–86.

    Article  PubMed  Google Scholar 

  70. Anderson ME, Moore TL, Hollis S, et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford). 2002;41:324–8.

    Article  CAS  Google Scholar 

  71. Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60:870–7.

    Article  PubMed  CAS  Google Scholar 

  72. Rajagopalan S, Pfenninger D, Somers E, et al. Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol. 2003;92:1310–5.

    Article  PubMed  CAS  Google Scholar 

  73. Goldberg J, Diesk A. Successful treatment of Raynaud’s phenomenon with pentoxifylline. Arthritis Rheum. 1986;29:1055–6.

    Article  PubMed  CAS  Google Scholar 

  74. Levien TL. Phosphodiesterase inhibitors in Raynaud’s phenomenon. Ann Pharmacother. 2006;40:1388–93.

    Article  PubMed  CAS  Google Scholar 

  75. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase Type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166:231–3.

    Article  PubMed  CAS  Google Scholar 

  76. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980–5.

    PubMed  CAS  Google Scholar 

  77. Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264–8.

    Article  PubMed  CAS  Google Scholar 

  78. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann Intern Med. 1994;120:199–206.

    PubMed  CAS  Google Scholar 

  79. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998;(2):CD000953.

    Google Scholar 

  80. Bettoni L, Geri A, Airò P, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol. 2002;21:244–50.

    Article  PubMed  CAS  Google Scholar 

  81. Chung L, Fiorentino D. A pilot trial of Treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol. 2006;54:880–2.

    Article  PubMed  Google Scholar 

  82. Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004;33:253–6.

    Article  PubMed  CAS  Google Scholar 

  83. Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon. A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56:3837–46.

    Article  PubMed  CAS  Google Scholar 

  84. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma. Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42:2646–55.

    Article  PubMed  CAS  Google Scholar 

  85. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud’s phenomenon. Ann Pharmacother. 2006;40:1998–2002.

    Article  PubMed  CAS  Google Scholar 

  86. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40:1038–43.

    Article  CAS  Google Scholar 

  87. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–93.

    Article  PubMed  CAS  Google Scholar 

  88. Matucci-Cerinic M, Seibold JR. Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford). 2008;47 Suppl 5:v46–7.

    Article  Google Scholar 

  89. Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol. 2006;18:594–600.

    Article  PubMed  CAS  Google Scholar 

  90. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801–8.

    PubMed  CAS  Google Scholar 

  91. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol. 2001;19:4–8.

    PubMed  CAS  Google Scholar 

  92. Rosato E, Borghese F, Pisarri S, et al. The treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol. 2009;28:1379–84.

    Article  PubMed  Google Scholar 

  93. Denton CP, Bunce TD, Dorado MB, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford). 1999;38:309–15.

    Article  CAS  Google Scholar 

  94. Matsumoto Y, Ueyama T, Endo M, et al. Endoscopic thoracic sympathicotomy for Raynaud’s phenomenon. J Vasc Surg. 2002;36:57–61.

    Article  PubMed  Google Scholar 

  95. Yee AM, Hotchkiss RN, Paget SA. Adventitial stripping: a digit saving procedure in refractory Raynaud’s phenomenon. J Rheumatol. 1998;25:269–76.

    PubMed  CAS  Google Scholar 

  96. Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol. 2003;30:1788–92.

    PubMed  Google Scholar 

  97. Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial sympathectomy. J Hand Surg Am. 2009;34:1454–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA

    Fredrick M. Wigley

Authors
  1. Fredrick M. Wigley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Wigley, F.M. (2011). Raynaud’s Phenomenon and Sjögren’s Syndrome. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_15

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation